首页> 美国卫生研究院文献>Journal of Biomedical Science >A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
【2h】

A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment

机译:癌胚抗原脉冲树突状细胞与破伤风类毒素混合并随后进行IL-2治疗的晚期大肠癌免疫治疗的I期临床研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTo better evaluate and improve the efficacy of dendritic cell (DC)-based cancer immunotherapy, we conducted a clinical study of patients with advanced colorectal cancer using carcinoembryonic antigen (CEA)-pulsed DCs mixed with tetanus toxoid and subsequent interleukin-2 treatment. The tetanus toxoid in the vaccine preparation serves as an adjuvant and provides a non-tumor specific immune response to enhance vaccine efficacy. The aims of this study were to (1) evaluate the toxicity of this treatment, (2) observe the clinical responses of vaccinated patients, and (3) investigate the immune responses of patients against CEA before and after treatment.
机译:背景为了更好地评估和提高基于树突状细胞(DC)的癌症免疫疗法的疗效,我们使用癌胚抗原(CEA)脉冲DC结合破伤风类毒素和随后的白介素2治疗对晚期大肠癌患者进行了临床研究。疫苗制剂中的破伤风类毒素用作佐剂,并提供非肿瘤特异性免疫应答以增强疫苗效力。这项研究的目的是(1)评估这种治疗的毒性,(2)观察接种疫苗的患者的临床反应,以及(3)研究患者在治疗前后对CEA的免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号